Open AccessAndrogen receptor variant-driven prostate cancer II: advances in laboratory investigations
Author(s) -
Changxue Lu,
Landon C. Brown,
Emmanuel S. Antonarakis,
Andrew J. Armstrong,
Jun Luo
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0217-3
Subject(s) - androgen receptor , prostate cancer , medicine , cancer research , cancer , disease , androgen , bioinformatics , computational biology , biology , hormone
The androgen receptor (AR) is a key prostate cancer drug target. Suppression of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing AR-directed therapies. AR-targeting agents impart therapeutic benefit, but lead to AR aberrations that underlie disease progression and therapeutic resistance. Among the AR aberrations specific to castration-resistant prostate cancer (CRPC), AR variants (AR-Vs) have emerged as important indicators of disease progression and therapeutic resistance.